The double opioid crisis: A call for balance

Marjolein J.M. Vranken, Marie Hélène D.B. Schutjens, Aukje K. Mantel-Teeuwisse*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalPharmacoepidemiology and Drug Safety
Volume28
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Funding

The Division of Pharmacoepidemiology and Clinical Pharmacology of Utrecht University is designated as a WHO Collaborating Centre for Pharmaceutical and Regulation. The WHO Collaborating Centre for Pharmaceutical Policy and Regulation receives no direct funding or donations from private parties, including pharma industry. Research funding from public‐private partnerships, eg, IMI, TI Pharma (www. tipharma.nl), is accepted under the condition that no company‐specific product or company related study is conducted. The Centre has received unrestricted research funding from public sources, eg, Netherlands Organization for Health Research and Development (ZonMW), the Dutch Healthcare Insurance Board (ZIN), EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board (MEB), and the Dutch Ministry of Health, Welfare and Sport.

Cite this